These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 20857202)

  • 1. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis.
    Mao C; Liao RY; Qiu LX; Wang XW; Ding H; Chen Q
    Mol Biol Rep; 2011 Apr; 38(4):2219-23. PubMed ID: 20857202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies.
    Cui D; Cao D; Yang Y; Qiu M; Huang Y; Yi C
    Mol Biol Rep; 2014 Mar; 41(3):1291-8. PubMed ID: 24390240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
    Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
    Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL
    Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
    Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
    J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis.
    Yuan ZX; Wang XY; Qin QY; Chen DF; Zhong QH; Wang L; Wang JP
    PLoS One; 2013; 8(6):e65995. PubMed ID: 23776587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF V600E mutation as a predictive factor of anti-EGFR monoclonal antibodies therapeutic effects in metastatic colorectal cancer: a meta-analysis.
    Wang Q; Hu WG; Song QB; Wei J
    Chin Med Sci J; 2014 Dec; 29(4):197-203. PubMed ID: 25429742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
    Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
    Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.
    Xu Q; Xu AT; Zhu MM; Tong JL; Xu XT; Ran ZH
    J Dig Dis; 2013 Aug; 14(8):409-16. PubMed ID: 23615046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
    Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
    Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
    Shinozaki E; Yoshino T; Yamazaki K; Muro K; Yamaguchi K; Nishina T; Yuki S; Shitara K; Bando H; Mimaki S; Nakai C; Matsushima K; Suzuki Y; Akagi K; Yamanaka T; Nomura S; Fujii S; Esumi H; Sugiyama M; Nishida N; Mizokami M; Koh Y; Abe Y; Ohtsu A; Tsuchihara K
    Br J Cancer; 2017 Nov; 117(10):1450-1458. PubMed ID: 28972961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
    BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
    Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A
    Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.
    Cappuzzo F; Varella-Garcia M; Finocchiaro G; Skokan M; Gajapathy S; Carnaghi C; Rimassa L; Rossi E; Ligorio C; Di Tommaso L; Holmes AJ; Toschi L; Tallini G; Destro A; Roncalli M; Santoro A; Jänne PA
    Br J Cancer; 2008 Jul; 99(1):83-9. PubMed ID: 18577988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
    Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer.
    Dono M; Massucco C; Chiara S; Sonaglio C; Mora M; Truini A; Cerruti G; Zoppoli G; Ballestrero A; Truini M; Ferrarini M; Zupo S
    Mol Med; 2013 Feb; 18(1):1519-26. PubMed ID: 23255073
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    van Brummelen EMJ; de Boer A; Beijnen JH; Schellens JHM
    Oncologist; 2017 Jul; 22(7):864-872. PubMed ID: 28576857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.